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Adverse effects and Drug Interactions Associated with Inhaled Recreational and 
Medical Marijuana 
Maisha Kelly Freeman, PharmD, MS, BCPS, FASCP and Pilar Z Murphy, PharmD, BCACP 
Samford University Global Drug Information Service McWhorter School of Pharmacy 
 
Abstract 
Objectives: To provide an overview of the addiction potential; adverse effects (e.g., cardiovascular, immune dysfunction, respiratory 
system, mental health disorders); drug interactions; effects of accidental exposure; crime statistics; and pharmacist’s considerations 
for the use of inhaled medical marijuana. Methods: A PubMed search was conducted from 1966 to March 2016 to identify articles in 
which the safety of inhaled medical marijuana was assessed.  Key MeSH search terms included medical marijuana with a subheading 
for adverse effect.  Only articles in adult patients were considered.  In addition, medical marijuana or cannabis plus one of the 
following search terms were searched: drug interactions, herb-drug interactions, drug-related side effects and adverse drug 
reactions, substance-related disorders, addiction, and abuse.   A free-text search was also conducted to identify articles not included 
in the MeSH term search.  A bibliographic search was also conducted. Articles were included if they addressed adverse effects of 
medical marijuana for the treatment of a condition.  Meta-analyses, randomized controlled clinical trials, and case reports were 
included in the review if the primary focus of the article related to the adverse effect profile of inhaled medical marijuana. Medical 
marijuana efficacy studies were not assessed. In the absence of this information, case reports or reports of inhaled recreational 
marijuana use was used. Studies were excluded if published in languages other than English.  In addition, studies highlighting 
mechanisms of action, studies of pharmacodynamics or pharmacokinetic effects were excluded, unless these effects were due to 
drug-drug interactions. Prescription products containing marijuana or derivatives were excluded from evaluation.  An Internet search 
was conducted to locate the most up-to-date information on the laws concerning medical marijuana. Key findings: A PubMed search 
revealed 58 articles and 28 of those studies were included in this review.   Several studies were located that evaluated the safety of 
medical marijuana; however, much of the review focused on inhaled, recreational marijuana use due to the paucity of information on 
inhaled medical marijuana.  Since marijuana is a Schedule1 product, few clinical studies have been conducted to determine the 
adverse event profile of the product. As a result, several articles that characterized recreational inhaled marijuana were included. 
Recreational inhaled marijuana use may be associated with an increase in cardiovascular (CV)/ cerebrovascular effects (CVA); 
however, conflicting information exists in the literature. Recreational marijuana use may also increase risky behaviors that increase 
the transmission of infectious diseases and respiratory diseases. Many of the studies were retrospective in nature; therefore, it was 
difficult to determine a cause and effect relationship between inhaled marijuana use and the development of adverse reactions or 
drug-drug interactions. Conclusions: There is a paucity of information related to the use of inhaled medical marijuana. Recreational 
marijuana use is associated with several adverse events including CV/CVA, respiratory, and transmission of infectious diseases. 
Theoretical literature indicates that medical marijuana may be associated with significant drug-drug interactions and adverse drug 
reactions. Legalization of medical marijuana may be associated with an increase in abuse/dependence and accidental exposures in 
children.  Pharmacists need to be educated regarding the appropriate use of medical marijuana to avoid adverse reactions and 
potential drug-drug interactions between medical marijuana and other products. 
 
Key words:  medical marijuana, cannabis, adverse effects, law 
 
Introduction 
Marijuana is the most commonly used illicit drug substance in 
the United States. 1 The Food and Drug Administration (FDA) 
currently classifies marijuana as a Schedule I drug under the 
Controlled Substances Act, declaring it to have no currently 
accepted medical use and a high potential for abuse.2  The 
term “medical marijuana” has been coined to describe the 
use of the whole, unprocessed marijuana plant or its extracts  
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to treat a disease or relieve symptoms. 3,4 The use of medical 
marijuana has gained significant momentum with the recent 
legalization of the product in many states. As of March 2016, 
23 states and Washington, DC have legalized and approved 
the use of medical marijuana.  In general, these state laws 
allow for the consumption of medical marijuana under the 
recommendation of a licensed medical professional and will 
allow patients to present a legal defense against marijuana 
possession charges if a medical need for the drug has been 
properly documented.   Most states require that patients and 
physicians have an established relationship prior to the 
recommendation of medical marijuana use, and maintain a 
formal registry of its users.  States require patients to register 
for an identification card and will permit caregivers to obtain 
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the medicinal marijuana for patients.  Of the 23 states, 
Arizona, Maine, Michigan, Nevada, New Hampshire, and 
Rhode Island will recognize other state registries through a 
reciprocity system.5 Marijuana is being used therapeutically 
for various conditions.  While all states have specific 
approved conditions for the use of cannabis, most also allow 
for the physician to determine “other debilitating illnesses” 
that may also be treated with marijuana.5,6 Table 1 provides 
an overview of the legal marijuana states and their approved 
medical conditions for use.   
 
The list of approved conditions for the use of medical 
marijuana varies from state to state.  The most commonly 
approved disease states include Alzheimer’s disease, 
amyotrophic lateral sclerosis (ALS), cachexia, cancer, Crohn’s 
disease, epilepsy and seizure disorders, glaucoma, hepatitis C, 
human immunodeficiency virus/acquired immunodeficiency 
syndrome (HIV/AIDS), multiple sclerosis  and muscle 
spasticity disorders, severe and chronic pain, severe nausea, 
and post-traumatic stress disorder (PTSD).5  Cannabis has 
been used to treat a number of disease states and associated 
symptoms.  However, data is lacking in human models and 
with the use of actual “medicinal marijuana” in its 
unprocessed form, as most studies evaluated the effects of 
the tetrahydrocannabinol (THC) derivatives, dronabinol and 
nabilone.  There is limited data to support the use of 
medicinal marijuana as a treatment option for Alzheimer’s 
Disease and amyotrophic later sclerosis (ALS). 7 However, 
other investigators have found that smoked and vaporized 
cannabis was associated with a reduction in significant pain 
from HIV-associated sensory neuropathy and central 
neuropathic pain and HIV/AIDS associated cachexia.  4,8-12  
 
Over the past 30 years, substantial research in human and 
animal models has shown that prolonged use of marijuana 
may lead to physical dependence and a withdrawal syndrome 
upon discontinuation.  Several mechanisms are thought to 
play a part in the drug reward system, and the resulting 
cannabis abuse or dependence.  There are two types of 
cannabinoid receptors, cannabinoid 1 (CB1) and cannabinoid 
2 (CB2).  The CB1 receptors are expressed in the central 
nervous system and are found mainly in the brain, kidney, 
liver, and lungs.13,14 The CB2 receptors are most commonly 
associated with the immune system.   In the brain, CB1 
receptors are most abundant in the cerebellum, basal ganglia, 
and hippocampus.14 These locations explain many of the 
negative effects seen on short-term memory, impaired motor 
skills, and delayed reaction time  when cannabinoids are 
inhaled and ingested.15,16  Research shows that CB1 receptors 
act as modulators of GABA release in the hippocampus.17The 
CB1 receptors are also found on glutamate and GABA neuron 
axon terminals in the hippocampus and decrease the 
excitability of neurons.  There they control the release of 
neurotransmitters, and it is thought that this is the primary 
means that cannabinoids inhibit hippocampal neuronal 
activity and disrupt memory.  Activation of the CB1 receptor 
affects the central nervous system in ways similar to those of 
other reward-enhancing drugs such as alcohol, cocaine, and 
opioids, and is the accepted mechanism for the addictive 
properties of cannabinoids.14,16-18        
 
Chronic use of illicit and medicinal marijuana may lead to 
dependence or addiction.  Chronic cannabis users develop 
tolerance to its effects and report being unable to control 
their use despite negative consequences.15  Mental health 
surveys indicated that cannabis dependence is the most 
common type of drug dependence after alcohol and 
tobacco.16 According to the National Institute on Drug Abuse, 
marijuana overstimulation of the endocannabinoid system 
can lead to addiction.  Approximately 9 percent of marijuana 
users will become dependent (frequency of use undefined), 
and 20 to 50% of daily users will become dependent.3,16     
 
Cannabis use disorder, defined as increased tolerance, 
compulsive use, craving, inability to cut down or control 
cannabis use, and withdrawal, is triggered by chronic 
marijuana use. 19 Patients with cannabis use disorders seeking 
discontinuation often report withdrawal symptoms including 
major mood changes, anxiety, appetite disturbance, 
depression, and personality changes.1,15 Compton et al 
evaluated the prevalence of marijuana use disorders and 
found that marijuana abuse or dependence increased by 18% 
from 30.2% in 1991-1992 to 35.6% in 2001-2002.  Current 
literature suggests that factors such as increased potency of 
marijuana may contribute to increased physical dependence.  
1,15  States with legalized medicinal marijuana currently have 
no statutes governing the potency of marijuana products, and 
there is no normalization of product potency.  As such, 
patients using medical marijuana may be at greater risk for 
addiction potential with chronic use.     
 
There is a perception that increased legalization may be 
associated with increased use because the public may 
consider that marijuana’s adverse effect profile is benign.   
Cerdá et al evaluated the relationship between state 
legalization of medical marijuana and marijuana use, abuse 
and dependence according to the National Epidemiologic 
Survey on Alcohol and Related Conditions (NESARC).  The 
investigators found that residents of states who had 
marijuana legalization laws had higher odds of marijuana use 
(OR, 1.92; 95% CI, 1.49 – 2.47) and marijuana 
abuse/dependence (OR, 1.81; 95% CI, 1.22 – 2.67) than 
residents of states without legalization status.  However, 
abuse/dependence was not more prevalent among users in 
these states (OR, 1.03; 95% CI, 0.67 – 1.60).  As a result, 
higher rates of abuse/dependence in the states with legalized 
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marijuana may be due to the higher rates of use in these 
states. 20,21  
 
Although an increasing number of states have passed laws 
and others have laws on the horizon, the long-term 
consequences of medical marijuana have not been fully 
elucidated. 5     
 
Recent changes in medical marijuana policies suggest greater 
acceptance of marijuana use in our society, and may cause 
users to feel it is a benign drug with a limited adverse side 
effect profile or potential for addiction.21The upsurge of 
dispensaries and patients growing their own medicinal supply 
of marijuana makes it imperative that the public and 
healthcare workers understand the possible therapeutic 
benefits of marijuana along with the known adverse health 
effects linked to marijuana.3 In addition, the role of 
pharmacists in educating patients who may be taking medical 
marijuana needs to be identified.  The purpose of this review 
is to provide an overview of the addiction potential; adverse 
effects (e.g., cardiovascular, immune dysfunction, respiratory 
system, mental health disorders); drug interactions; effects of 
accidental exposure; crime statistics; and pharmacist’s 
considerations for the use of medical marijuana. 
 
Methods 
A PubMed search was conducted from 1966 to March 2016 
to identify articles in which the safety of inhaled medical 
marijuana was assessed.  Key MeSH search terms included 
medical marijuana with a subheading for adverse effect. Only 
articles in adult patients were included. In addition, medical 
marijuana or cannabis plus one of the following search terms 
were searched: drug interactions, herb-drug interactions, 
drug-related side effects and adverse drug reactions, 
substance-related disorders, addiction, and abuse.   A free-
text search was also conducted to identify articles not 
included in the MeSH term search.  A bibliographic search 
was also conducted. An Internet search was conducted to 
locate the most up-to-date information on the laws 
concerning medical marijuana.  Articles were included if they 
addressed adverse effects of medical marijuana for the 
treatment of a condition.  Meta-analyses, randomized 
controlled clinical trials, and case reports were included in the 
review if the primary focus of the article related to the 
adverse effect profile of medical marijuana. Medical 
marijuana efficacy studies were not assessed. In the absence 
of this information, case reports or reports of recreational 
marijuana use was used.  Studies were excluded if published 
in languages other than English. Studies focusing on 
mechanisms of action, studies of pharmacodynamics or 
pharmacokinetic effects, unless these effects were due to 
drug-drug interactions were also excluded.  We excluded 
articles that did not evaluate adverse events of medical 
marijuana  as the primary purpose.  Prescription products 
containing marijuana or derivatives were excluded from 
evaluation.   
 
Results 
A PubMed search revealed 58 articles with medical marijuana 
and adverse effect as a subheading.  A total of 11 articles 
were identified with a MeSH search for medical marijuana 
and adverse effect.  A total of 28 articles were reviewed that 
related to marijuana addiction, adverse reactions, drug 
interactions, and accidental exposures. Of the articles 
identified by PubMed and bibliographic searches, one was a 
meta-analysis, 17 were clinical studies, and 10 were case 
reports/series.  Table 2 provides a description of the clinical 
studies used in this review.  
 
Cardiovascular / Cerebrovascular effects 
Marijuana has well established effects on the cardiovascular 
system and may negatively impact patients with various 
disease states including cardiovascular disease, hypertension, 
and angina. Existing evidence supports the adverse 
cardiovascular effects of marijuana use.  Cannabinoids have 
complex effects on blood pressure.  The acute effects of 
recreational cannabis include an increase in blood pressure, 
and then decreased vascular resistance-induced orthostatic 
hypotension. 18,22,23   Smoked marijuana causes a dose-
dependent increase in heart rate, increases myocardial 
oxygen demand, and decreases oxygen supply.  Cannabis use 
may potentially cause tachycardia and transient hypertension 
and may increase the risk of myocardial infarction (MI).23 
 
No reports of cardiovascular (CV)/cerebrovascular (CVA) 
complications associated with medical marijuana use were 
identified. As a result, CV/CVA adverse events with 
recreational cannabis use were explored.  Several clinical 
studies evaluating CV/CVA effects of inhaled medical 
marijuana have been published. 23-26 Recreational marijuana 
use in the age group (20-92 years, mean age 44 years) most 
prone to coronary artery disease has increased.   The risk of 
MI onset in the hour following marijuana use was almost five 
times greater than baseline. A rapid decline in risk occurred 
the second hour after smoking marijuana.  23,24 Marijuana 
may be a rare trigger of MI in patients with coronary artery 
disease.23,25-26 
 
Several cases of myocardial infarction following recreational 
marijuana use have been reported, however, little is known 
about the actual association between marijuana and 
myocardial infarction (MI).23,25,27-28  In one report, a 30-year-
male with no family history of cardiovascular disease 
experienced a ST elevation MI caused by thrombosis of the 
descending artery.  The patient had no prior medical history 
and denied taking any medications.  He reported smoking 
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recreational marijuana two to three times weekly, with his 
last consumption being 2 hours prior to symptom onset.29 
 
In another report, a 26-year-old male with no cardiovascular 
disease risk factors other than smoking, was admitted to the 
emergency department following recreational cannabis and 
cigarette smoking three hours prior to symptom onset.25 
Yurtdas et al also summarized 13 published cases of 
marijuana-induced MI.  Of these cases, most patients (n = 
12/13) presented with chest pain and MI, and the time from 
cannabis consumption to symptom onset ranged from one 
hour to five days.  
 
Since marijuana is also an analgesic, chronic users may not 
experience the same pain syndrome associated with 
myocardial infarctions and may delay getting medical 
assistance.30  In addition, there have been case reports of 
cerebral ischemic events in recreational marijuana users.31-34 
All of this information is limited by few case reports and 
several methodological flaws.  Furthermore, long-term 
effects of medical marijuana use have not been evaluated 
and the majority of adverse events were associated with 
recreational use.35 
 
Immune dysfunction / Cancer reports 
Gordan et al systematically reviewed the literature to 
determine medical adverse effects/consequences associated 
with marijuana for recreational use.35Since marijuana has 
been associated with immune dysfunction, marijuana use 
may increase the risk of a variety of infectious diseases. 
Recreational marijuana use has been associated with 
outbreaks in tuberculosis (TB), Neisseria meningitidis, and 
sexually transmitted diseases.36-40 There may also be a risk for 
marijuana users to develop severe steatosis (fatty 
degeneration) and fibrosis in the liver.  This effect was 
observed in patients with chronic hepatitis C who had a liver 
biopsy and were daily marijuana users.41 Marijuana use has 
also been associated with an increased risk of cancer; 
however, studies evaluating the potential carcinogenic 
activity of marijuana had several methodological flaws that 
limit the interpretation of the literature.  There may be an 
increased risk of bladder cancer, head/neck, and lung cancer 
in habitual marijuana smokers.42-44  
 
Respiratory Disorders 
Cannabis smoke contains many of the same carcinogens 
found in cigarette smoke; however, the effects of cannabis 
smoking on the respiratory system remain unclear.  
Marijuana smokers may have an increased risk of respiratory 
dysfunction (e.g., chronic bronchitis, increased mucus 
production, wheezing, increased hyperinflation, Forced Vital 
Capacity [FVC], and residual volume in respiratory function 
tests).45-48  Inhaled marijuana may increase the risk of lung 
cancer, emphysema, bronchitis, reduced lung density, 
wheeze, phlegm, and cough. 15,49Studies over the past two 
decades have shown that regular recreational marijuana 
smokers report more chronic bronchitis than non-smokers 
and also have higher rates of respiratory infections and 
pneumonia. 15,18 In a study assessing cannabis-related adverse 
events leading to hospitalization, respiratory system 
disorders were observed among 31.0% of patients (n=62/200) 
and consisted of dyspnea (n=16), hemoptysis (n=10), and 
spontaneous pneumothorax (n=7).  The corresponding 
incidence was 1.6 per 1000 (95% CI 1.2, 2.0) among recent 
cannabis users.24Respiratory disorders associated with 
cannabis may be exacerbated in patients with underlying 
asthma and chronic obstructive pulmonary disease (COPD).49 
 
Cannabis smokers inhale more deeply than tobacco smokers, 
hold their smoke longer, and thereby retain more 
carcinogens, tar and particulate matter.  Chronic cannabis 
smokers show pathological changes in lung cells that precede 
the development of cancer.15  There is conflicting evidence as 
to whether smoking marijuana causes lung and other types of 
cancers, suggesting the need for further study in this area.   
 
Marijuana has also been identified as a risk factor for 
developing bullous disease and pneumothorax.  The 
incidence of bullae was higher in marijuana smokers in a 
retrospective evaluation of habitual marijuana smokers 
referred for treatment of spontaneous pneumothorax.  
Incidence of bullae was higher in marijuana smokers 
compared to non-marijuana smokers (7/10 vs. 3/10 patients, 
respectively, p<0.05).  In another retrospective case series of 
17 patients less than 40 years of age presenting with 
spontaneous pneumothoraxes, 16 patients reported smoking 
marijuana daily for a mean of 8.8 years and tobacco for 11.8 
years.  These findings have led to the terms “marijuana lung” 
and “bong lung” to describe patients developing large 
peripheral paraseptal lung bullae.49 
 
There is conflicting information regarding the adverse effects 
of medical marijuana on respiratory disorders (specifically 
cancers); however, asthma and COPD symptoms may be 
exacerbated with inhaled medical marijuana. 
 
Mental Health Disorders 
Repeated cannabis use causes behavioral alterations, and 
increased risk of mental illness including increased rates of 
psychosis, depression, and anxiety.3,13,18 Studies report that 
chronic cannabis use results in at least a twofold increase in 
schizophrenia and psychotic symptoms, and those with 
schizophrenia are more likely to use marijuana.15,18 According 
to the National Institute on Drug Abuse, ingesting large doses 
of cannabis may cause an acute psychosis presenting with 
hallucinations, delusions, and a loss of the sense of self.3  
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Chronic users with cannabis use disorders have been found to 
be six times more likely to have mood or anxiety disorders; 
and exacerbation of psychiatric disorders has been associated 
with repeated cannabis use.50Cannabis withdrawal also 
causes a variety of psychological withdrawal symptoms 
including anger, irritability, aggression, anxiety, and sleep 
difficulties.13 Cannabis intoxication presents with a plethora 
of psychological manifestations including euphoria, 
relaxation, impaired memory and concentration, anxiety, 
panic attack, and psychosis.50  
 
There appears to be mixed reports about posttraumatic 
stress disorder (PTSD) symptomatology following marijuana 
use.  Wilkinson et al evaluated marijuana use in symptom 
severity and violent behavior in patients with posttraumatic 
stress disorder. 21  Patients in the study were drawn from the 
national evaluation of specialized intensive PTSD programs 
implemented by the Northeast Program Evaluation Center of 
the Veterans Health Administration from 1992 to 2011.  A 
sample of 47,130 patients with PTSD were included.  Patients 
were excluded if they had problematic alcohol use (more 
than two drinks on one occasion), those with any drug use 
(other than marijuana) within 30 days of admission, and 
those who entered treatment on transfer from an inpatient 
or residential program that restricted their access to alcohol 
and drugs.  A total of 12,770 patients met the inclusion 
criteria and were classified into the following groups:  no 
marijuana use (“never users”, n=11,344), those reporting 
marijuana use at admission, but not at four months after 
discharge (“stoppers”, n=299), those reporting use at 
admission and four months after discharge (“continuing 
users”, n=296), and those reporting no use at admission but 
reporting use four months after discharge (starters, n=831).  
A total of 850 subjects were randomly selected from the 
never-user group, yielding a total sample of 2,276 veterans.  
Patients were evaluated at four months to assess PTSD 
symptom severity, employment status, violent behavior and 
composite measures of alcohol and drug use from the 
Addiction Severity Index (ASI).  Marijuana use after treatment 
was associated with higher PTSD symptoms, more violent 
behavior, and alcohol use. 21  
 
Pierre et al reports psychosis associated with cannabis use in 
a 24-year-old man who was hospitalized for insomnia, 
irritability and aggressiveness two years after military service.  
He was given quetiapine 100 mg/day and had a rapid 
resolution of symptoms.  Six months later, the patient was 
rehospitalized with psychotic symptoms after converting to 
medical marijuana with an increased frequency of twice daily 
use.  After a course of aripiprazole and substance abuse 
treatment, the patient discontinued cannabis use and 
remained psychotic free.52 
 
Greer et al evaluated PTSD symptoms collected during 80 
psychiatric evaluations of patients applying to the New 
Mexico Medical Cannabis Program from 2009 to 2011.  
Results indicated that a greater than 75% reduction in 
symptoms, as measured by the Clinician Administered 
Posttraumatic Scale for DSM-IV (CAPS), was observed in 
patients using cannabis compared when they were not users 
of cannabis.53    
 
Increased psychotic symptoms in patients with PTSD 
receiving marijuana were identified by Bonn-Miller et al.54  
Patients (n=432, male) in the study participated in a 
residential PTSD treatment at a Department of Veterans 
Affairs (VA) Medical Center between 1994 and 2000.The 
average length of stay in the program was 69.86 days.  
Approximately 56.9% of the patients were white and the 
remaining patients were identified as Hispanic/Latino 
American (14.1%), African American (13.9%), mixed ethnicity 
(6.9%), Native American (5.3%), Asian/Pacific Islander (1.6%), 
and “Other” (1.2%). Patients were excluded from the 
residential program if that had current psychotic symptoms, 
had substance use within 15 days of the start of treatment, or 
had medical conditions with a high probability of interfering 
with or preventing psychological treatment. Patients were 
evaluated at treatment intake, discharge and 4-month follow 
up.  Approximately 23.1% of patients reported alcohol use, 
8.1% reported cannabis use, 3% reported opiate use, 2.1% 
reported cocaine use and 1.9% reported amphetamine use.  
The frequency of cannabis use was correlated with follow up 
cannabis use.  Change in PTSD Checklist-Military (PCL-M) 
scores between treatment intake and discharge were 
significantly predictive of greater frequency of cannabis use 
during the 30 days before the 4-month follow up (P<0.05).54 
 
Approximately 20-30% of patients who smoke marijuana for 
recreational use report anxiety and panic attacks.  Low dose 
marijuana appears to be sedating, whereas, larger doses 
appear to induce anxiety.  It has not been determined if 
marijuana is associated with an increased risk of developing 
bipolar disorder.  The data regarding an increased risk of 
depression associated with marijuana use is conflicting.  In 
addition, marijuana worsens psychotic symptoms and 
outcomes in patients with schizophrenia or other psychotic 
disorders.  55 
 
Hospitalizations 
A cross sectional study in an urban academic hospital in 
Aurora, Colorado was conducted to determine if the rates of 
emergency department (ED) visits possibly related to 
cannabis use have increased disproportionately among out-
of-state residents, as compared with Colorado residents.    
The study was conducted between 2012 – 2014.  Residency 
of patients was determined by zip codes given by the patients 
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upon registering in the ED.  Patient files with ICD-9 codes for 
cannabis used within the designated time period were 
evaluated.  The visits were due to psychiatric (26%), 
gastrointestinal symptoms (27%), and cardiopulmonary (16%) 
symptoms. The majority of patients were male (65%) and 
white (46%).  Other races identified were black (38%) and 
other (16%).  The rates of ED visits possibly related to 
cannabis use among out-of-state residents doubled from 85 
per 10,000 visits in 2013 to 168 per 10,000 visits in 2014 (P = 
0.001).  No change was observed in ED visits possibly related 
to cannabis between 2012 and 2013 among out-of-state 
residents or Colorado residents.  In addition, data from the 
Colorado Hospital Association did not indicate a significant 
change from 2011 to 2012 in the ED visits among out-of-state 
residents; however, from 2012 to 2014, the statewide rate 
among out-of-state residents increased from 78 per 10,000 
visits in 2012 to 112 per 10,000 visits in 2013 to 163 per 
10,000 visits in 2014 (rate ratios, 1.44 (2012 to 2013) and 
1.46 (2013 to 2013); P <0.001 for both comparisons).  Rates 
of ED use increased for Colorado residents from 2011 to 
2014, the rate of ED visits possibly related to cannabis use 
increased from 61 to 70 to 86 to 101, respectively, per 10,000 
visits (rate ratios, 1.14 [2011 to 2012], 1.24 [2012 to 2013], 
and 1.17 [2013 to 2014]; P<0.001 for all comparisons). 56  This 
study is limited by its small sample size and it only reflects 
cannabis use in one state. 
 
Miscellaneous adverse drug reactions 
Several investigators have evaluated adverse drug reactions 
associated with medical marijuana.  Wang et al evaluated the 
adverse effects associated with medical cannabinoid use (oral 
∆-9-tetrahydrocannabinol or ∆-9 tetrahydrocannabinol-
cannabidiol and oromucosal ∆-9-tetrahydrocannabinol-
cannabidiol were evaluated) in a systematic review and meta 
analysis.57  No studies involving the smoking of marijuana 
were included.  A total of 31 studies (n = 1932 patients) was 
reviewed.  In these studies, the median duration of cannabis 
exposure was two weeks (range, 8 hours to 12 months) and 
patients received cannabis for chronic conditions (e.g., 
cancer, multiple sclerosis).  A total of 164 serious adverse 
events occurred in patients taking cannabinoid therapy 
compared to 60 among the control group (either placebo or 
standard care). The most common adverse events were 
relapse of multiple sclerosis, vomiting, and urinary tract 
infection.  Among the randomized controlled studies, no 
statistically significant differences between serious adverse 
events were observed between groups (RR, 1.04; 95% CI, 0.78 
– 1.39).  Adverse events were reported as respiratory 
(16.5%), gastrointestinal disorders (16.5%), nervous system 
disorders (15.2%), general disorders and administration-site 
conditions (12.85%), renal/urinary disorders (9.8%); 
neoplasm (benign and malignant) (8.5%), and psychiatric 
disorders (6.7%)  The incidence for nonserious adverse events 
was significantly higher in patients taking cannabinoids than 
among patients assigned to the control group; (RR, 1.86; 95% 
CI, 1.57-2.21; P<0.001).  Central nervous system (23.1%) and 
psychiatric disorders (10.3%) were the most common serious 
adverse events reported in the observational studies with no 
control group.  However, this study was limited because it did 
not include reports of adverse events due to inhaled cannabis 
and only short-term use was evaluated (up to 12 months).57,58 
 
Drug Interactions 
The major active ingredient in marijuana is delta-9-
tetrahydrocannabinol (THC).  This agent exerts its effects by 
binding to cannabinoid receptors that are present mainly in 
the central nervous system (CNS).  Binding of THC to these 
receptors causes several therapeutic and psychoactive 
effects. 59 Effects are also associated with modulatory effects 
in neurotransmitters (e.g., acetylcholine, norepinephrine, 
dopamine, serotonin, gamma aminobutyric acid, glutamate, 
and D-aspartate).59-61 The metabolism of THC has not been 
completely elucidated.  Several enzymes appear to play a role 
in metabolism including CYP2C9 and CYP3A4.  As a result, 
medications that are metabolized by either of these 
pathways are subjected to an increased risk of interactions.62 
 
There is a paucity of information related to drug-drug 
interactions with marijuana.  Several interactions exist 
between dronabinol (marinol) and commercially available 
agents.  In addition, major interactions exist between 
dronabinol and cocaine, ethanol, and droperidol.  Other 
interactions include anxiolytics, barbiturates, disulfiram, 
monoamine oxidase inhibitors (MAOIs), protease inhibitors, 
selective serotonin reuptake inhibitors (SSRIs), sildenafil, 
sedatives, theophylline, tricyclic antidepressants, and 
warfarin.59,63  Most of the interactions cited in drug 
interaction monographs are theoretical in nature based on 
the proposed mechanism of action of dronabinol and the 
potential offending agent; however, case reports/clinical 
studies indicating a potential interaction have occurred with 
anticholinergics, barbiturates, disulfiram, lithium, protease 
inhibitors (e.g., indinavir, nelfinavir), SSRIs (e.g., fluoxetine), 
sildenafil, theophylline, tricyclic antidepressants, opioid 
analgesics, and warfarin.59,61,62,64-66 
 
Kleinloog et al evaluated the effects of THC in a placebo-
controlled, cross-over study in 49 healthy male patients who 
were mild cannabis users.  Subjects received a single dose of 
olanzapine (10 mg) or two oral doses of diphenhydramine (15 
mg, used as a positive control for sedation) on 
intrapulmonary THC administration (2, 4, and 6 mg with 90 
minute intervals).  Psychomimetic symptoms, as assessed by 
the Positive and Negative Syndrome Scale (PANSS), were 
observed after THC administration (20.6% increase on 
positive subscale P<0.001) and the visual analogue scale for 
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psychedelic effects (+10.7 mm on feeling high).  After THC 
and olanzapine administration, the positive subscale 
increased by only 13.7% and feeling high by 8.7 mm 
(P=0.066).  Only one-third of patients did not show an 
increase in psychomimetic symptoms after THC alone.  Of the 
responders, olanzapine significantly reduced the effects of 
THC (P = 0.005).64 
 
Accidental exposures 
According to the American Association of Poison Control 
Centers’ National Poison Data System (NDPS) annual report 
from 2013, marijuana was mentioned a total of 5,033 times 
for exposures and THC analogs were mentioned 2,666 times.  
The largest number of exposures were in patients aged >20 
years (n=614) and the smallest in children < 5 years (n=256).  
Unintentional exposures were cited in 398 cases involving 
marijuana and 86 cases with THC homologs.  No major deaths 
were reported associated with marijuana use; however, three 
deaths were reported with the use of THC homologs.67 
 
Wang et al evaluated the number of calls to Poison Control 
Centers as a function of medical marijuana legalization in a 
retrospective review of the American Association of Poison 
Control Centers National Poison Data System between 
January 1, 2005 and December 31, 2011.68   State laws 
regarding marijuana use was classified as nonlegal if they had 
not passed legislation, transitional if legislation was in effect 
between 2005 and 2011, and decriminalized if laws were in 
effect before 2005.  A total of 985 unintentional marijuana 
exposures were reported during that time period in children 
less than 9 years.  Of the 985 exposures, 496 were in nonlegal 
states, 93 in transitional states, and 396 in decriminalized 
states.  The majority of exposures were in males between 1.5 
to 2 years.  A variety of clinical events were reported; 
however, neurological effects were reported most frequently.  
Exposures in decriminalized states were associated with 
increased healthcare utilization, as measured by call rates 
(difference, +28.3%; 95% CI, 19-38%), more moderate to 
major clinical effects (OR, 2.1; 95% CI, 1.4 to 3.1) and more 
critical care admissions (OR, 3.4; 95% CI, 1.8 to 6.5) compared 
with exposures from nonlegal states.  The most common 
symptom associated with medical marijuana was 
drowsiness/lethargy in patients in nonlegal (20%), transitional 
(30%), and decriminalized (37%) states.  No changes in call 
rate in nonlegal states were observed; however, the call rate 
in decriminalized states increased by 30.3% calls per year.  
Similarly, call rates in transitional states increased to 11.5% 
per year.68 
 
Crime / Car Accident Fatalities 
Medical marijuana dispensaries are perceived to be 
associated with increased criminal activity in proximity to 
dispensary location; however, few investigators have 
evaluated whether or not the dispensaries are associated 
with increased criminal activity.  Although medical marijuana 
dispensaries produce conditions associated with an increased 
crime rate (e.g., burglary, robbery, assault, etc), the typical 
patient population (e.g., older White men) is not believed to 
be a high risk population for perpetrating crimes.69 Kepple et 
al evaluated the crime rates associated with medical 
marijuana dispensaries in Sacramento, CA in an ecological, 
cross-section study.  Results indicated that violent crime rates 
were not significantly related to the presence of a medical 
marijuana dispensary.  However, a significant increase in 
crime rates were observed when there was a high population 
of individuals in the community between the ages of 15-24 
years, high percentage of one-person households, high 
unemployment rate and high percentage of commercial 
zoning locations.69  In another study, ease of access to 




Pharmacists may be asked to provide counseling to patients 
who are using medical marijuana.  As a result, pharmacists 
need to know potential adverse effects, drug-drug 
interactions, and policies / procedures associated with 
dispensing medical marijuana.  Several states have proposed 
that pharmacists be responsible for dispensing medical 
marijuana and although state laws may sanction this activity, 
federal laws will be violated.71  In most states, pharmacists 
are not allowed to recommend a source or provide 
instructions on how to obtain medical marijuana.  
Furthermore, Pharmacy and Therapeutics committees may 
be asked for guidance and or policy considerations regarding 
the dispensing of medical marijuana.72,73  The American 
Society of Health System Pharmacists (ASHP) “oppose(s) state 
legislation that authorizes the use of medical marijuana until 
there is sufficient evidence to support its safety and 
effectiveness and a standardized product that would be 
subject to the same regulations as a prescription drug 
product.”  ASHP encourages research into the effectiveness, 
safety and clinical use of medical marijuana and will advocate 
for development processes that would ensure 
standardization of the products.  In addition to encouraging 
the DEA to eliminate barriers to medical research of medical 
marijuana (e.g., potentially reclassifying the product to 
something other than a Schedule 1 controlled substance), 
they oppose storage, procurement, and distribution of the 
product by licensed pharmacies/health facilities for uses 
other than research.74 A general Internet search yielded 
several resources that may assist practitioners in learning 
more about medical marijuana.  One school of pharmacy, St. 
John Fisher College offered a day-long medical marijuana 
training session. 75 Several continuing education classes have 
been dedicated to the topic as well.  The Cannabis Training 
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Institute provides a Cannabis Industry Certification for 
individuals completing the course.  This program is a training 
and certification resource for cannabis businesses, 
entrepreneurs, clinicians, and policymakers.76 
 
Clinical questions are still unanswered related to the use of 
medical marijuana including which method of delivery is best 
to product therapeutic effect without producing untoward 
adverse effects. The most efficacious method of delivery has 
not been established.  In addition, the content of THC in 
cannabis may vary according to geographic origin, the part of 
the plant used, methods for storage, and cultivation 
techniques. 77 Cultivation can also be associated with 
contaminants in the cannabis.  Biological contaminants of 
cannabis plants include fungus and bacteria. 
 
At least two states with legalized medical marijuana prohibit 
the use of smoked marijuana.5  In addition, the appropriate 
dosage of medical marijuana needs to be determined.  If 
dispensed, pharmacists need to be able to ensure the 
potency of the products and ensure that the products are not 
contaminated with harmful substances. 
 
Conclusion 
The legalization of marijuana has led to the misconception 
that it is a safe, natural product with few side effects and no 
serious drug or disease state interactions.  21  Although a 
limited amount of information was located for medical 
marijuana, this information is based on the assumption that 
medical and recreational marijuana adverse effects are 
similar.  The efficacy of medical marijuana in several disease 
states has not been elucidated; however, use may be 
associated with significant drug-drug interactions and adverse 
drug reactions.  In addition, legalization has been associated 
with increased marijuana abuse/dependence and accidental 
exposures in children. Increased case reports of 
cardiovascular events following recreational marijuana use, 
its potential to exacerbate respiratory disorders, and the 
potential for psychiatric changes establishes the need for 
extensive study and education to minimize these events.   In 
order to appropriately counsel patients, pharmacists need to 
be informed about the use of marijuana.  Additional training 
is necessary and essential for pharmacists to understand and 
recognize the potential interactions with chronic medications, 
especially those used for marijuana approved disease states.  
Extensive investigation is needed to fully understand the 
pharmacologic effects of marijuana for treating disease states 
and to minimize the detrimental effects experienced by 
chronic users.  Pharmacists play a key role in medication 
management, and the legalization of medical marijuana 
complicates this role with little guidance.  Additional studies 
need to be performed to determine long-term adverse 
effects of medical marijuana in various populations. 
 




1. Compton WM, Grant BF, Colliver JD, Glantz MD, 
Stinson FS. Prevalence of marijuana use disorders in 
the United States: 1991-1992 and 2001-2002. JAMA. 
2004; 291:2114-2121. 
2. Bostwick JM. Blurred boundaries: the therapeutics 
and politics of medical marijuana. Mayo Clin Proc. 
2012; 87:172-186. 
3. National Institute on Drug Abuse. Research report 
series. Marijuana. 
http://www.drugabuse.gov/sites/default/files/mjrrs
_3.pdf.  Accessed January 12, 2015. 
4. Whiting PF, Wolff RF, Deshpande S, et al. 
Cannabinoids for medical use: a systematic review 
and meta-analysis. JAMA. 2015;313:2456-2473. 
5. ProCon.org Website. 23 Legal Medical Marijuana 
States and DC.  
http://medicalmarijuana.procon.org/view.resource.
php?resourceID=000881. Last modified March 14, 
2016. Accessed April 6, 2016. 
6. Seamon MJ. The legal status of medical marijuana. 
Ann Pharmacother. 2006; 40:2211-2215. 
7. Belendiuk KA, Baldini LL, Bonn-Miller MO, et al. 
Narrative review of the safety and efficacy of 
marijuana for the treatment of commonly state 
approved medical and psychiatric disorders. Addict 
Sci Clin Pract. 2015; 10:10. 
8. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, et al. 
Cannabis in painful HIV-associated sensory 
neuropathy: a randomized placebo-controlled trial. 
Neurology.2007; 68: 515–521.  
9. Phillips TJ, Cherry CL, Cox S, Marshall SJ, Rice AS. 
Pharmacological treatment of painful HIV-associated 
sensory neuropathy: a systematic review and meta-
analysis of randomised controlled trials. PLoS One. 
2010; 5(12): e14433.   
10. Abrams DI, Guzman, M. Cannabis in cancer care. Clin 
Pharmacol Ther. 2015;97: 575–586. 
11. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, 
Aweeka FT, et al. Short-term effects of cannabinoids 
in patients with HIV-1 infection: a randomized, 
placebo-controlled clinical trial. Ann Intern Med. 
2003;139:258–66.   
 
 
12. Haney M, Gunderson EW, Rabkin J, Hart CL, et al. 
Dronabinol and marijuana in HIV-positive marijuana 
smokers caloric intake, mood, and sleep.  J Acquir 
Immune Defic Syndr. 2007 15;45:545-54. 
Original Research  PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                      2016, Vol. 7, No. 2, Article 6                               INNOVATIONS in pharmacy   9 
 
  
13. Ramesh D, Schlosburg JE, Wiebelhaus JM, Lichtman 
AH. Marijuana dependence: not just smoke and 
mirrors. Inst Lab Anim Res J.  ILAR J.  2011; 
52(3):295-308. 
14. Laaris N, Good CH, Lupica CR. Delta-9-
tetrahydrocannabinol is a full agonist at CB1 
receptors on GABA neuron axon terminals in the 
hippocampus. Neuropharmacology. 2010; 59:121-
127. 
15. Hall W, Solowij N. Adverse effects of cannabis. 1998; 
Lancet. 1998; 352: 1611–1116. 
16. Hall W. The adverse health effects of cannabis use: 
What are they, and what are their implications for 
policy? Int J Drug Policy. 2009; 20:458-466. 
17. Katona I, Sperlagh B, Sik A, et al. Presynaptically 
located CB1 cannabinoid receptors regulate 
GABA release from axon terminals of specific 
hippocampal interneurons. J Neurosci.  1999; 
19:4544–4558. 
18. Greydanus DE, Hawver EK, Greydanus MM, & 
Merrick J. Marijuana: current concepts. Front Public 
Health. 2013; 1(42):1-17. 
19. American Psychiatric Association. Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition, 
DSM-5. Washington D.C.: American Psychiatric 
Association; 2013. 
20. Cerdá M, Wall M, Keyes KM, Galea S, Hasin D.  
Medical marijuana laws in 50 states:  investigating 
the relationship between state legalization of 
medical marijuana and marijuana use, abuse, and 
dependence.  Drug Alcohol Depend. 2012; 120:22-
27. 
21. Wilkinson ST, D’Souza DC. Problems with the 
medicalization of marijuana.  JAMA.  2014;311:2377-
2378. 
22. Davis, M. P. Oral nabilone capsules in the treatment 
of chemotherapy-induced nausea and vomiting and 
pain. Expert Opin Investig Drugs. 2008;17:85-95. 
23. Mittleman MA, Lewis RA, Maclure M, et al. 
Triggering myocardial infarction by marijuana. 
Circulation. 2001; 103:2805-2809. 
24. Jouanjus E, Leymarie F, Tubery M, Lapeyre-Mestre 
M. Cannabis-related hospitalizations: unexpected 
serious events identified through hospital databases. 
Br J Clin Pharmacol. 2011; 71: 758–765.  
25. Yurtdas M, Aydin MK. Acute myocardial infarction in 
a young man; fatal blow of the marijuana: a case 
report. Korean Circ J.  2012; 42:641-645.   
 
 
26. Nawrot TS, Perez L, Kunzli, N, Munters E, and 
Nemery, B. Public health importance of triggers of 
myocardial infarction: a comparative risk 
assessment. Lancet. 2011; 377:732-740. 
27. Frost L, Mostofsky E, Rosenbloom JI, et al.  
Marijuana use and long-term mortality among 
survivors of acute myocardial infarction.  Am Heart J. 
2013;165:170-175. 
28. Rodondi N, Pletcher MJ, Liu K, Hulley SB, Sidney S.  
Marijuana use diet, body mass index, and 
cardiovascular risk factors (from CARDIA study).  Am 
J Cardiol.  2006;98:478-484. 
29. Cappelli F, Lazzeri C, Gensini GF, and Valente, S. 
Cannabis: a trigger for acute myocardial infarction? 
A case report. J Cardiovasc Med (Hagerstown). 2008; 
9:725-728. 
30. Malinowska B, Baranowska-Kuczko M, Schlicker E.  
Triphasic blood pressure responses to cannabinoids: 
do we understand the mechanism?  Br J Pharmacol.  
2012; 165:2073-2088. 
31. Zachariah SB.  Stroke after heavy marijuana smoking.  
Stroke.  1991;22:406-409. 
32. Geller T, Loftis L, Brink DS.  Cerebellar infarction in 
adolescent males associated with acute marijuana 
use. Pediatrics.  2004;113:e365-370. 
33. Finsterer J, Christian P, Wolfgang K.  Occipital stroke 
shortly after cannabis consumption.  Clin Neurol 
Neurosurg.  2004;106:305-308. 
34. Herning RI, Better WE, Tate K, et al.  Marijuana 
abusers are at increased risk for stroke.  Preliminary 
evidence from cerebrovascular perfusion data.  Ann 
NY Acad Sci.  2001;939:413-415. 
35. Gordan AJ, Conley JW, Gordan JM.  Medical 
consequences of marijuana use: a review of current 
literature.  Curr Psychiatry Rep. 2013;15:419.   
36. Munchkhof WJ, Konstantinos A, Wamsley M, 
Mortlock M, Gilpin C.  A cluster of tuberculosis 
associated with use of a marijuana water pipe.  Int J 
Tuberc Lung Dis. 2003;7:860-865. 
37. Oeltmann JE, Oren E, Haddad MB, et al. Tuberculosis 
outbreak in marijuana users, Seattle Washington, 
2004.  Emerg Infect Dis.  2006;12:1156. 
38. Krause G, Blackmore C, Wiersma S, et al.  Marijuana 
use and social networks in a community outbreak of 
meningococcal disease.  South Med J. 2001;94:482-
485. 
39. Finn R, Groves C, Coe M, Pass M, Harrison LH. Cluster 
of serogroup C meningococcal disease associated 




40. Liau A, di Clemente RJ, Wingood GM, et al.  
Associations between biologically confirmed 
marijuana use and laboratory-confirmed sexually 
Original Research  PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                      2016, Vol. 7, No. 2, Article 6                               INNOVATIONS in pharmacy   10 
 
  
transmitted diseases among African American 
adolescent females.  Sex Transm Dis.  2002;29:387-
390. 
41. Hezode C, Zafrani ES, Roudot-Thoraval F, et al.  Daily 
cannabis use:  a novel risk factor of steatosis severity 
in patients with chronic hepatitis C.  
Gastroenterology.  2008;134:432-439. 
42. Nieder AM, Lipke MC, Madjar S. Transitional cell 
carcinoma associated with marijuana:  case report 
and review of the literature.  Urology.  2006;67:200. 
43. Berthiller J, Lee YC, Boffetta P, et al.  Marijuana 
smoking and the risk of head and neck cancer: 
pooled analysis in the INHANCE consortium.  Cancer 
Epidemiol Biormarkers Prev.  2009;18:1544-1551. 
44. Taylor III FM. Marijuana as a potential respiratory 
tract carcinogen:  a retrospective analysis of a 
community hospital population.  South Med J.  
1988;81:1213-1216. 
45. Friedman GD, Polen MR, Sadler M, Sidney S, Tekawa 
IS.  Health care use by frequent marijuana smokers 
who do not smoke tobacco.  West J Med. 
1993;158:596-601. 
46. Taylor DR, Poulton R, Moffit TE, Ramankutty P, Sears 
MR.  The respiratory effects of cannabis dependence 
in young adults.  Addiction.  2000;95:1669-1677. 
47. Taylor DR, Fergusson DM, Milne BJ, et al.  A 
longitudinal study of the effects of tobacco and 
cannabis exposure on lung function in young adults.  
Addiction.  2002;97:1055-1061. 
48. Moore BA, Augustson EM, Moser RP, Budney AJ.  
Respiratory effects of marijuana and tobacco use in a 
U.S. sample.  J Gen Intern Med.  2005;20:33-37. 
49. Lutchmansingh D, Pawar L, Savici D. Legalizing 
Cannabis: A physician’s primer on the pulmonary 
effects of marijuana. Curr Respir Care Rep. 
2014;3(4):200-205.  
50. Danovitch I, Gorelick DA.  State of the art treatments 
for cannabis dependence.   Psychiatr Clin North Am. 
2012; 35(2): 309–326. 
51. Wilkinson ST, Stefanovics E, Rosenheck RA. 
Marijuana use is associated with worse outcomes in 
symptom severity and violent behavior in patients 
with posttraumatic stress disorder.  J Clin Psychiatry. 
2015; 76(9):1174-1180. 
52. Pierre JM.  Psychosis associated with medical 
marijuana:  risk vs. benefits of medicinal cannabis 
use. Am J Psychiatry. 2010;167:598-599. 
 
 
53. Greer GR, Grob CS, Halberstadt AL.  PTSD symptom 
reports of patients evaluated for the New Mexico 
Medical Cannabis Program.  J Psychoactive Drugs. 
2014;46:73-77. 
54. Bonn-Miller MO, Vujanovic AA, Drescher KD.  
Cannabis use among military veterans after residual 
treatment for posttraumatic stress disorder. Psychol 
Addict Behav. 2011;25:485-491. 
55. Medical marijuana and the mind.  Harvard Medical 
Journal.  2010; 26:1-3. 
56. Kim HS, Hall KE, Genco EK, Van Dyke M, Barker E, 
Monte AA.  Marijuana tourism and emergency 
department visits in Colorado.  N Engl J Med. 
2016;374(8):797-798. 
57. Wang T, Collet JP, Shapiro S, Ware MA.  Adverse 
effects of medical cannabinoids:  a systematic 
review.  CMAJ. 2008;178:1669-1678. 
58. Borgelt LM, Franson KL, Nussbaum AM, Wang GS.  
The pharmacological and clinical effects of medical 
cannabis.  Pharmacotherapy. 2013;33:195-209. 




Accessed April 12, 2016. 
60. Seamon MJ, Fass JA, Maniscalco-Feichti MM, Bu-
Shraie NA.  Medical marijuana and the developing 
role of the pharmacist.  Am J Health-Syst Pharm.  
2007;64:1037-1044. 
61. Dronabinol, THC.  Lexi-Comp Online.  
http://www.crlonline.com.ezproxy.samford.edu/lco/
action/doc/retrieve/docid/patch_f/6795.  Accessed 
April 12, 2016. 
62. Lindsey WT, Stewart D, Childress D.  Drug 
interactions between common illicit drugs and 
prescription therapies. Amer J Drug Alcohol Abuse.  
2012;38:334-343. 










# .Accessed April 12, 2016. 
64. Kleinloog D, Liem-Moolenaar M, Jacobs G, Klaassen 
E, de Kam M, Hijman R, van Gerven J. Does 
olanzapine inhibit the psychomimetic effects of Δ⁹-
tetrahydrocannabinol? J Psychopharmacol. 2012; 
26:1307-1316. 
65. Stout SM, Cimino NM. Exogenous cannabinoids as 
substrates, inhibitors, and inducers of human drug 
metabolizing enzymes: a systematic review. Drug 
Metab Rev. 2014; 46:86-95. 
Original Research  PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                      2016, Vol. 7, No. 2, Article 6                               INNOVATIONS in pharmacy   11 
 
  
66. Abrams DI, Couey P, Shade SB, Kelly ME, Benowitz 
NL. Cannabinoid-opioid interaction in chronic pain. 
Clin Pharmacol Ther. 2011;90:844-851. 
67. Mowry JB, Spyker DA, Cantilena LA, McMillan N, 
Ford M.  2013 Annual report of the American 
Association of Poison Control Centers’ National 
Poison Data System:  31st Annual report. Clin Tox. 
2014;52:1032-1283.  Available at: 
https://aapcc.s3.amazonaws.com/pdfs/annual_repo
rts/2013_NPDS_Annual_Report.pdf.  Accessed 
January 9, 2015. 
68. Wang GS, Roosevelt G, Le Lait MC, Martinez EM, 
Bucher-Bartelson B, Bronstein AC, Heard K. 
Association of unintentional pediatric exposures 
with decriminalization of marijuana in the United 
States. Ann Emerg Med. 2014;63:684-689. 
69. Kepple NJ, Friesthler B.  Exploring the ecological 
association between crime and medical marijuana 
dispensaries.  J Stud Alcohol Drugs.  2012;73:523-
530. 
70. Masten SV, Guenzburger GV. Changes in driver 
cannabinoid prevalence in 12 U.S. states after 
implementing medical marijuana laws. J Safety Res. 
2014;50:35-52. 
71. Benson L.  Pharmacists ready, worry over new role:  
Medical pot dispenser.  MPR News. 
http://www.mprnews.org/story/2014/08/09/pharm
acists-pot-dispenser.   Accessed January 14, 2015. 
72. Marcoux RM, Larrat P, Vogenberg FR.  Medical 
marijuana and related legal aspects.  P &T.  
2013;3:612, 615-619. 
73. Daigle L.  Medical marijuana.  ASHP Policy Analysis.  
http://www.ashp.org/DocLibrary/Advocacy/Analysis
Paper/ASHP-Medical-Marijuana-Policy-Analysis.aspx 
.  Accessed January 9, 2015. 
74. Official language of professional policies approved 
by the 2011 ASHP House of Delegates.  1101 Medical 
Marijuana.  
http://www.ashp.org/DocLibrary/Policy/HOD/Officia
lLang2011Policies.aspx.  Accessed January 9, 2015. 
75. St. John Fisher College News.  Wegmans School of 
Pharmacy hosts pharmacist training session on 
medical marijuana.  
http://www.sjfc.edu/news/detail.dot?id=d624d03b-
676f-45c0-871b-dbac4bd13871. Accessed April 11, 
2016. 
76. Cannabis Training Institute.  Cannabis Industry 
Certification.  
https://cannabistraininginstitute.com/cannabis-
industry-certification/.  Accessed April 11, 2016.  
77. Greenwell GT. Medical marijuana use for chronic 
pain:  risks and benefits.  J Pain Pall Care 











Original Research  PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                      2016, Vol. 7, No. 2, Article 6                               INNOVATIONS in pharmacy   12 
 
  
Table 1: Summary chart of States with Legal Medical Marijuana5 
 
State Year Passed Approved Conditions 
1. Alaska 1998 Cachexia, cancer, chronic pain, epilepsy and other disorders characterized by 
seizures, glaucoma, HIV or AIDS, multiple sclerosis and other disorders characterized 
by muscle spasticity, and nausea. Other conditions are subject to approval by the 
Alaska Department of Health and Social Services. 
2. Arizona 2010 Cancer, glaucoma, HIV/AIDS, Hepatitis C, ALS, Crohn's disease, Alzheimer's disease, 
cachexia or wasting syndrome, severe and chronic pain, severe nausea, seizures 
(including epilepsy), severe or persistent muscle spasms (including multiple sclerosis). 
Starting Jan.1, 2015, PTSD was added to the list. 
3. California 1996 AIDS, anorexia, arthritis, cachexia, cancer, chronic pain, glaucoma, migraine, 
persistent muscle spasms, including spasms associated with multiple sclerosis, 
seizures, including seizures associated with epilepsy, severe nausea; Other chronic or 
persistent medical symptoms. 
4. Colorado 2000 Cancer, glaucoma, HIV/AIDS positive, cachexia; severe pain; severe nausea; seizures, 
including those that are characteristic of epilepsy; or persistent muscle spasms, 
including those that are characteristic of multiple sclerosis. Other conditions are 
subject to approval by the Colorado Board of Health. 
5. Connecticut 2012 "Cancer, glaucoma, positive status for human immunodeficiency virus or acquired 
immune deficiency syndrome [HIV/AIDS], Parkinson's disease, multiple sclerosis, 
damage to the nervous tissue of the spinal cord with objective neurological indication 
of intractable spasticity, epilepsy, cachexia, wasting syndrome, Crohn's disease, 
posttraumatic stress disorder, or... any medical condition, medical treatment or 
disease approved by the Department of Consumer Protection..." 
 
On Mar. 14, 2016, the Connecticut Department of Consumer Protection announced 
six new qualifying conditions: sickle cell disease, post laminectomy syndrome with 
chronic radiculopathy, severe psoriasis and psoriatic arthritis, amyotrophic lateral 
sclerosis, ulcerative colitis, and complex regional pain syndrome. 
6. District of Columbia 2010 Azidothymidine/Protease inhibitor therapy, Cancer, Chemotherapy/Radiotherapy, 
Glaucoma, HIV/AIDS, 
Multiple sclerosis/Severe and persistent muscle spasms 
7. Delaware 2011 ALS, Alzheimer's disease, Cachexia or wasting syndrome, Cancer, Decompensated 
cirrhosis (Hepatitis C), HIV/AIDS, Intractable nausea, Multiple sclerosis/Severe and 
persistent muscle spasms, 
Severe/Debilitating pain unresponsive to previously prescribed medication or surgical 
measures for more than 3 months or for which other treatment options produced 
serious side effects, PTSD 
8. Hawaii 2000 Cachexia or wasting syndrome, Cancer, Epilepsy/Seizure disorder, Glaucoma, 
HIV/AIDS, Multiple sclerosis/Severe and persistent muscle spasms, Severe nausea, 
Severe pain, PTSD 
9. Illinois 2013 Includes about 40 chronic diseases.  Alzheimer's disease agitation, Amyotrophic 
lateral sclerosis, Arnold-Chiari malformation and Syringomelia, Spinocerebellar Ataxia 
(SCA), Cachexia/wasting syndrome, Cancer, Causalgia, Chronic inflammatory 
Demyelinating Polyneuropathy, Crohn's disease, Dystonia, Fibrous dysplasia, 
Glaucoma, Hepatitis C, HIV/AIDS, Hydrocephalus, Hydromyelia syringomyelia, 
Interstitial Cystitis, Lupus, Multiple Sclerosis, Muscular dystrophy, Myasthenia Gravis, 
Myoclonus, Nail-patella syndrome or residual limb pain, Neurofibromatosis, 
Parkinson's Disease, Reflex Sympathetic Dystrophy, Rheumatoid arthritis, Severe 
fibromyalgia, Sjogren's Syndrome, Spinal cord disease, Spinal cord injury, Tarlov cysts, 
Tourette’s Syndrome, Traumatic brain injury and post-concussion syndrome 
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10. Maine 1999 Epilepsy/Seizure disorders, Glaucoma, Multiple sclerosis/Muscle spasticity disorders, 
Nausea or vomiting as a result of AIDS or cancer chemotherapy 
11. Maryland 2014 Anorexia or Wasting syndrome, Cachexia, Seizures, Severe nausea, Severe or chronic 
pain, Severe or persistent muscle spasms or other conditions approved by the 
Commission. 
12. Massachusetts 2012 ALS, Cancer, Crohn's disease, Glaucoma, Hepatitis C, HIV/AIDS, Multiple sclerosis, 
Parkinson's disease 
13. Michigan 2008 ALS, Alzheimer's disease agitation, Cachexia or wasting syndrome, Cancer, Crohn's 
disease, Epilepsy/Seizure disorders, Glaucoma, Hepatitis C, HIV/AIDS, Multiple 
sclerosis/Other muscle spasm disorders, Nail patella, PTSD, Severe and chronic pain, 
Severe nausea 
14. Minnesota 2014 ALS, Cancer (if the underlying condition or treatment produces severe or chronic 
pain, nausea or severe vomiting, or cachexia or severe wasting), Crohn's disease, 
Epilepsy/Seizure disorders, Glaucoma, HIV/AIDS, Multiple sclerosis/Severe &  
persistent muscle spasms, Terminal illness with a life expectancy of under one year, 
Tourette's syndrome>  Patients with intractable pain may become eligible to receive 
medical marijuana August 2016. 
15. Montana 2004 Cachexia or wasting syndrome,  Cancer, Crohn's disease, Epilepsy/Seizure disorders, 
Glaucoma, HIV/AIDS, Multiple sclerosis/Muscle spasticity, Severe nausea,  Severe or 
chronic pain 
16. Nevada 2000 AIDS, Cachexia, Cancer, Glaucoma, Persistent muscle spasms, PTSD, Seizures, Severe 
nausea or pain 
17. New 
Hampshire 
2013 ALS, Alzheimer's disease agitation, Cancer, Chronic pancreatitis, Crohn's disease, 
Glaucoma, Hepatitis C, HIV/AIDS, Injuries that significantly interferes with daily 
activities as documented by the patient's provider, Multiple sclerosis, Muscular 
dystrophy, Severely debilitating or terminal medical condition or its treatment that 
has produced at least one of the following: elevated intraocular pressure, cachexia, 
chemotherapy induced anorexia, wasting syndrome, severe pain that has not 
responded to previously prescribed medication or surgical measures or for which 
other treatment options produced serious side effects, constant or severe nausea, 
moderate to severe vomiting, seizures, or severe, persistent muscle spasms; Spinal 
cord injury or disease, Traumatic brain injury 
18. New Jersey  2010 Epilepsy/Seizure disorder, Multiple sclerosis, Intractable skeletal muscular spasticity, 
Glaucoma, Severe or chronic pain, Severe nausea/vomiting, cachexia, or wasting 
syndrome resulting from HIV/AIDS or cancer, ALS, Terminal cancer, Muscular 
dystrophy, Inflammatory bowel disease including Crohn’s disease, Terminal illness if 
prognosis < 12 months of life  
19. New Mexico 2007 ALS, Cancer, Cervical dystonia, Crohn's disease, Damage to the nervous tissue of the 
spinal cord with intractable spasticity, Epilepsy, Glaucoma, Hepatitis C infection, 
HIV/AIDS, Hospice patients, Huntington's disease, Inflammatory Autoimmune-
mediated Arthritis, Intractable nausea/vomiting, Multiple sclerosis, Painful peripheral 
neuropathy, Parkinson's disease, PTSD, Severe anorexia/cachexia, Severe chronic 
pain, ulcerative colitis, spasmodic torticollis 
20. New York 2014 ALS, Cancer, Epilepsy, HIV/AIDS, Huntington's disease, Inflammatory bowel disease, 
Multiple sclerosis, Neuropathies, Parkinson's disease, Spinal cord damage causing 
spasticity. 
The Department of Health commissioner has the discretion to add or delete 
conditions and must decide whether to add Alzheimer's, muscular dystrophy, 
dystonia, PTSD, and rheumatoid arthritis within 18 months of the law becoming 
effective. 
21. Oregon 1998 Cancer, Cachexia, Epilepsy/Seizure disorder, Glaucoma, HIV/AIDS, Multiple 
sclerosis/Persistent muscle spasms, Severe nausea, Severe pain 
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22. Rhode Island 2006 Alzheimer's Disease agitation, Cachexia/Wasting syndrome, Cancer, Crohn's disease, 
Epilepsy/Seizure disorder, Glaucoma, Hepatitis C, HIV/AIDS, Multiple sclerosis/Severe 
& persistent muscle spasms, Severe debilitating chronic pain, Severe nausea 
23. Vermont 2004 Cachexia/Wasting syndrome, Cancer, Chronic, debilitating disease treatment which 
produces severe, persistent symptoms, HIV/AIDS, Multiple sclerosis, Seizures, Severe 
nausea, Severe pain 
24. Washington 1998 Anorexia, Cachexia, Cancer, Chronic renal failure, Crohn's disease, Diseases which 
result in nausea, vomiting, wasting, appetite loss, cramping, seizures, muscle spasms, 
or spasticity, when those conditions are unrelieved by standard treatments or 
medications, Epilepsy, Glaucoma, Hepatitis C with debilitating nausea or intractable 
pain, HIV/AIDS, Intractable pain (defined as pain unrelieved by standard treatment or 
medications), Multiple sclerosis 
*ALS = Amyotrophic lateral sclerosis 
+PTSD = Posttraumatic Distress Disorder 
HIV = Human Immunodeficiency Virus 
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Table 2:  Summary of clinical data assessing adverse drug reactions with medical marijuana 
 
Reference Study Design Patient 
Demographics 









Female:  1258 
with an acute MI 




Compared the reported 
use of marijuana in the 
hour preceeding 
symptoms of MI onset to 
its expected frequency 
using self-matched 
controlled data 
124 (3.2%) reported 
smoking marijuana 
in the prior year, 37 
within 24 hours and 




were more likely to 
be men (94% vs. 
67%, P<0.001), 
current cigarette 
smokers (68% vs. 
32%, P<0.001), and 
obese (43% vs. 
32%; P=0.008.  
These patients 
were less like to 
have a history of 
angina (12% vs, 
25%, P<0.001) or 
hypertension (30% 
vs. 44%; P =0.002).  
The risk of MI was 
elevated 4.8 times 
over baseline (95% 





may rarely trigger 
AMI. 









hospitals (n=6) in 
the Toulouse area 
(France) between 
January 2004 and 
December 2007 
in relation to the 
use of cannabis. 
 
Of the 200 
patients, 153 
(76.5%) were 
men; mean age 
was 28 years 
 
Cannabis use was 
identified through ICD-10 
codes and systematic 
review of medical charts.   
 
Cannabis use was 
validated in 41.9% 
(294/701) of previously 
selected hospitalizations, 
which correlated to 43.6% 
(232/532) of selected 
patients.  The final sample 
included 224 
hospitalizations (n=200 
patients).   
619 adverse events 
occurred, one led 
to death. Cannabis 




of total) and 
involved 57.5% of 
patients.   Incidence 
of psychiatric 
disorders was 2.9 
per 1000 among 
recent users, and 5 
per 1000 among 
regular users.  




can lead to 
hospitalizations. 
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Reference Study Design Patient 
Demographics 
Patient Characteristics Results Conclusion 
  
CNS disorders were 
the second most 
identified organ 
system (15.8% of 
toal adverse 
reactions that 
affected 44% of the 













occurred for 9.5% 
of the total AEs and 
involved 29% of 
patients.   The 
incidence of CV 
events was 1.5 per 
1000 among recent 
users and 2.6 per 
1000 among regular 
users. A total of 17 
extracardiac 
vascular disorders 
were reported and 
4 of these were 
CVA. 




28-year old man 





Smoking cannabis twice 
weekly for the prior 8 
years (last consumption 3 
hours before onset of 
symptoms).  Also a 
cigarette smoker. 





marijuana use may 
be associated MI 
symptoms. 
Nawrot et al.26 Meta-regression 
analysis to 
determine 
triggers of MI at 
an individual and 
population level. 
Mean age of 
patients ranged 
from 44 years to 
72 years. 
 
Most studies had 
a time window 
before onset of 
A total of 36 studies were 
investigated; 13 types of 
triggers for acute MI, 28 
case-crossover studies, 7 
time-series, and one case-
control study. 
 
 The prevalence of 
marijuana exposure 
was 0.2%; OR 4.8 
(95% CI, 2.9-9.5%). 
Population 
attributable factors 
(PAF):  0.75% (95% 




traffic and exposure 
to particulate 
matter air pollution 
were contributors 
to air pollution. 
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Reference Study Design Patient 
Demographics 
Patient Characteristics Results Conclusion 
MI ranging from 
less than 2 hours 
to 1 day (except 
respiratory 
infections which 
ranged from 1 to 
10 days). 






enrolled in 1989 
to 1996 and 
followed up for 
mortality using 
the National 
Death Index.  A 
total of 3,886 
patients 
hospitalized in 64 
centers 
nationwide were 
interviewed for a 
median of 4 days. 
 
All marijuana 
users were <63 
years, so patients 
in this age range 
were included.  
The final sample 
size was 2,097. 
 
The average age of 
patients reporting 
marijuana use was 43.7 
years, 6% were female, 
78% were white and 35% 
had some college.  Most 
of these patients were 
current smokers (67%). 
After 12.7 years, 
519 patients died as 
a result of their MI 
including 22 of the 
109 patients 
reporting marijuana 
use died at the time 
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Reference Study Design Patient 
Demographics 
Patient Characteristics Results Conclusion 





5,115 black and 
white adults 
between 18-30 
years in age in 
1985 to 1986. A 








was given to 
assess current 




Most marijuana users 
(89%) reported using 
marijuana for <1,800 days 
over 15 years (average 10 
days/month). A total of 37 
participants (1%) used 
marijuana for >3600 days 
(20 days/month).   
Higher marijuana 
use was associated 
with being male, 
tobacco use, use of 
other ilicit drug, 
less education, 
lower income.  
Higher use was also 
associated with 
higher physical 





Marijuana use was 
associated with 
higher triglyceride 
levels (P <0.001).  





the changes are 
unlikely to be 
clinically significant.  
Marijuana use was 
also associated with 
higher triglyceride 
use. 
Marijuana use was 
not independently 
associated with BMI 
and cardiovascular 
risk factors in 
young, healthy 
adults; however, 
these results are 
confounded by 
higher alcohol use 
in these patients. 





reported to the 
ED with chest 
pain radiating 
from  neck to jaw. 
Patient had no family 
history of coronary artery 
disease. 
BMI=28 
15-pack cigarette smoking 
history. 
 
Reported using cannabis 
2-3 times a week since his 
adolescent years; last 
consumption was 2 hours 
before symptom onset.  





recovered and was 
discharged 7 days 
after admission. 
Cannabis use may 
be  associated with 












history of 1 pack 
and up to seven 
marijuana 
No significant differences 
were observed in platelet 
function after smoking 
marijuana. 
Patient experienced 
a left basal ganglia 
infarct. 
After 3 months of 
physician and 
occupational 
therapy, the patient 
experienced 
marked 
improvement of his 
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Reference Study Design Patient 
Demographics 
Patient Characteristics Results Conclusion 
cigarettes per day neurological 
deficits. 
Geller et al.32 Retrospective 











Male adolescent patients  
(n=3) with ischemic 
cerebellar stroke after use 
of marijuana. 












marijuana use may 
be a risk factor for 
stroke in childhood. 









marijuana 250 mg 
Patient also smoked up to 
20 cigarettes per day.  
Patient smoked marijuana 
cigarette 2 hours before 
hospitalization. 
Patient experienced 




dismissed after 3 
days. 









Blood flow velocity from 
cerebral arteries using 
transcranial Doppler 
sonography was evaluated 
for a month of monitored 
abstinence to determine if 
perfusion changes in early 
abstinence were a part of 
marijuana withdrawal 
syndrome or permanent 
cerebrovascular deficit. 
Marijuana users 
had a significantly 
higher pulsatility 
idex (PI) than 
control subjects on 
both cerebral 
arteries (p<0.01).  
No changes were 
observed for PI for 
middle and anterior 
cerebral arteries.  
Chronic marijuana 
use may be a risk 
factor for stroke. 
Munchkhof et 
al.36 






45 contacts had a 
marijuana water 
pipe 
5 cases of pulmonary TB 
were identified.  All cases 
were Australian-born 
Caucasian male (median 
age 20 years). 
Transmission of TB 
occurred with 
sharing a marijuana 
water pipe (OR, 
2.22; 95% CI, 0.96-
5.17).   
 
All 5 cases were 
culture positive, 
and 4 were sputum 
AFB smear positive. 
All cases received 
directly observed 
therapy (DOT) and 
completed 
treatment. 
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Demographics 
Patient Characteristics Results Conclusion 
Oeltmann et 
al.37 




Cluster of TB 
cases in Seattle 
from February to 
April 2004 
East-African immigrants 
with histories of 
incarceration and illicit 
drug use. 




October 2004.  Four 
patients had 
confirmed TB.  All 
patients were 
unemployed and 
had histories of 
incarceration and 
illicit drug use. 
“Hotboxing” 
(smoking marijuana 
inside a closed car 
with friends) 
appeared to fuel 
transmission of TB. 















close contacts of 
the infected 
people. 






shared a variety of 
social activities. 
Social networks and 
marijuana exposure 
may help locate 
close contacts of 
patients with 
meningococcal 
disease and help 
prevent other 
infections. 





Cases were 18-21 
years of age had 
a diagnosis of N 
meningitides of 
the same strain. 
All transmissions 
appeared to have 
occurred at a May 14th 
party at a college. 
A large number of 
people reported 
marijuana and 
alcohol use at the 
party. 
Transmission may 
have occurred due 
to binge drinking 
and smoking. 
Liau et al. 40  Self-administered 
survey and face 








Average patient age was 
16 years (SD, 1.2 years); 
majority were full-time 
students (81.2%).  
Approximately 20% 
reported having a paying 
job and 28% tested 
positive for at least one of 
the three STDs tested. 
Of the study 
patients, 5.4% 
tested positive for 
marijuana.  These 
adolescents were 
more likely to test 
positive for 
Neisseria gonorrhea 
(adjusted OR, 3.4) 
and Chlamydia 
trachomatis (AOR, 
3.9).  They were 
more likely to avoid 
condoms in the 
previous 30 days 
(AOR, 2.9) and to 
have not used 
condoms 
consistently in the 
Marijuana use may 
increase risky sexual 
behavior in 
adolescents. 
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Patient Characteristics Results Conclusion 
previous 6 months 
(AOR, 3.6). 











Patients were categorized 
as cannabis nonusers 
(63.5%), occasional 
cannabis smokers (12.4%), 
or daily cannabis smokers 
(24.1%). 
 
Approximately 71% were 
male, route of 
transmission was IV drug 
use (44.1%) or blood 
transfusion (30.2%).  The 
majority of patients had 
HCV genotype 1 (62.5%). 
 
Median cannabis 
consumption was 4 
cigarettes/month and 
24.1% of patients were 
daily cannabis users and 






more frequent with 









was associated with 
daily use of 
cannabis (OR, 2.1; 
95% CI, 1.01-1.45).   
Marijuana use may 











History of heavy 
marijuana use (up 
to 5 cigarettes for 
more than 30 
years). 
Patient presented with 
gross hematuria over the 
course of 2 months. 
After a confirmed 
large papillary 
lesion was 
observed on the 





were normal after a 
3-month 
surveillance.  The 
patient stopped 
smoking marijuana. 
The patient’s only 











A total of 4,029 
head and neck 
cancer (HNC) and 




Patients ranged in age 
from 15-79 years.  
Approximately 10.1% of 
cases and 14.8% of 
controls were marijuana 
smokers.  Sources of 
information was random 
digit dialing, cancer 
screening clinics, 
neighborhood, hospital 
The risk of HNC was 
not increased with 
ever marijuana 
smoking (OR, 0.88; 
95% CI, 0.67 – 
1.16).   
Infrequent 
marijuana use does 
not increase the risk 
of HNC. 
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over 4 years were 
assessed in 
patients under 40 









A total of 887 patients 
were screened.  A total of 
10 patients were included.  
Six patients were male.  
The age range of the 
patients was between 28-
39 years.  Patients were 
categorized as heavy 
(daily use), regular 
(Frequent, but less than 
daily use), possible, and 
infrequent. 
 
Sites of carcinoma 
included oropharynx 
(n=4), larynx (n=4), and 
lung (n=2).  A total of 9 
lesions were squamous 
cell carcinoma and one 
was small cell anaplastic 
carcinoma. 
Five patients had a 
documented 
history of heavy 
marijuana smoking.  
Two patients were 
described as regular 
users.  One patient 
was a possible 
marijuana smoker.  
Two patients had 
no documentation 
of marijuana use.   
Regular use of 
marijuana may be a 
















program who had 
at least one 
health check up 
between July 
1979 and 
December 1985.  
The purpose was 
to determine the 
healthcare usage 




A total of 14,600 
respondents to the 
tobacco-marijuana survey 
responded smoking 
marijuana more than 6 
times in their lifetime. 
 
Marijuana smokers 
(n=746) and nonmarijuana 
smokers (n=709) were 
evaluated.  A total of 486 
pairs had medical charts 
reviewed.  A total of 70 
were excluded which left 
a total of 452 marijuana 
smokers and 450 
nonsmokers. 
Approximately 66% 
of subjects were 
male and the 
majority were 
between ages 25-





had a lower 
educational level 




reported more days 
ill with a cold, flu, 
Marijuana smokers 
were associated 
with small, but 
significant increases 
in outpatient visits. 
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or sore throat in 
the past year 
compared to 
nonsmokers.  A 









At least one 
outpatient visit for 
respiratory 
problems was made 
by 36% of the 
marijuana smokers 
vs. 33% of 
nonsmokers.   




943 adults born 
in Dunedin, New 
Zealand in 
1972/73 were 
evaluated at 21 
years of age. 
Tobacco and marijuana 
history was obtained from 
a self-administered 
questionnaire.  Subjects 
also completed a 
questionnaire for lung 
function.FEV1 and FVC 
was also assessed. 
A total of 588 non-
smokers, 264 
tobacco-only 




and 63 who smoked 
tobacco and 
cannabis were 
included.  A total of 
91 subjects were 
cannabis-
dependent.  The 
mean cannabis use 
was 230 times (95% 
CI, 193.6, 266.4) 
during the previous 
12 months, 
compared to 40 
(95% CI, 31.3, 48.7) 





(after controlling for 
tobacco use) had a 
significant increase 
in wheezing apart 
from colds (61%; 
p<0.05), exercise-
related shortness of 
breath (65%; 
p<0.05), nocturnal 
wakening with chest 
tightness (72%; 
p<.05) and morning 
sputum production 
(144%; p<0.001). 




Out of a cohort of 
1037 subjects, a 
group of 900 
young adults 
served as the 
Cannabis and tobacco use 
was documented at each 
age with a standard 
interview.  Lung function 
was also evaluated. 
Subjects who used 
cannabis on 900 or 
more occasions had 
a mean FEV1/VC 




use and decline in 
FEV/VC was 
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cohort.  Subjects 
were born in 
Dunedin, New 
Zealand in 1972/3 
were studied at 
ages 18, 21, and 
26 years. 
 
Results were available for 
930 subjects. 
7.2%, 2.6%, and 5% 
less than non users 
at ages 18, 21, and 
26, respectively. 
observed. 




6,728 adults aged 




health sections of 
the NHANES III 
questionnaire in 
1998 and 1994. 
Marijuana smokers 
reported smoking an 
average of 10.2 days of 
the previous 30 days.  
Approximately 16% 
reported daily or nearly 
daily use.  Smokers were 
more likely to be male, 
white, younger, and single 
compared to nonsmokers.  
Approximately 77% of 
marijuana smokers also 
smoked tobacco 
cigarettes. 
Reports of chronic 
bronchitis 8.1% vs. 
3.2%), cough 
(21.7% vs. 3.8%), 
phlegm (16.9% vs. 
3.5%), and chest 





compared to non 
smokers. (P<0.05).  
Shortness of breath 
(23.7% vs. 33.4%) 
and FEV1/FVC ratio 














Marijuana use was 
associated with an 
increased risk of 
many respiratory 
symptoms. 








Mean age: 51.7 
(SD =8.6(years, 
96.7% male, 21.2 
African American, 
married:  40.7%, 
mean education 
level: 12.9 years 
(SD 1.9). 
 
Mean length of 
Never-users (group 1, 
n=850) 
Stoppers (group 2, n=299) 
Continuing users (group 3, 
n=296) 
Starters (group 4, n=831) 
PTSD symptom 






Continuing users:  




Marijuana use was 
associated with 
higher PTSD 
symptoms at follow 
up compared to 
never users.   
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stay 42.5 days  
Violence (group 4 
>1,2,3) 





0.93 (0.068)  
Starters: 1.25 
(0.040) 







Stoppers:  0.079 
(0.011) 
Continuing users: 





Drug abuse (Groups 
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study to assess 
differences in 
PTSD symptoms 
with and without 
the use of 
cannabis. 
 
First 80 patients 
evaluated for 
participation in 









Scale (CAPS) for 
DSM-IV was 
assessed. 




reductions of total 
CAPS scores were 
observed when 
patients were using 
cannabis 
(22.5±16.9) 








reductions in core 
symptom cluster of 
re-experiencing 
(Criterion B) which 
decreased from 




(Criterion C) which 
decreased from 
38.2 ± 8.4 to 8.7 ± 
8.0; p<0.0001); and 
hyperarousal 
(Criterion D) which 
decreased from 




Cannabis use is 
associated with 
PSTD reduction in 
symptoms in some 
patients; however, 
additional clinical 
trials need to be 
conducted to 
determine the 
efficacy of cannabis 







to VA residential 
rehabilitation 
program 
Substance use patterns of 
male, VA patients who 
were admitted to 
treatment residency 
program. 
Change in PCL-M 
scores was not a 
significant predictor 
of alcohol or opiate 
use. 
 
A post hoc analysis 
indicated that 








lower levels of 
change in PTSD 
symptom severity 
during the course of 
residential 
treatment for PTSD 
were more likely to 
use cannabis after 
discharge from 
treatment. 
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cannabis use during 
the 30 days before 
4-month follow up. 
Hospitalizations 
Kim et al.56 Cross-sectional 






2012 -2014 and 
residency was 
determined by 
the zip codes. 
Hospital has 100,000 
emergency department 
(ED) visits per year.  
Findings were confirmed 
with data from more than 
100 hospitals reported to 
the Colorado Hospital 
Association from 2011 
through 2014. 
 
Female:  35% 
Black:  38% 
White:  46% 




ED visits possibly 
related to cannabis 
use among out-of-
state residents 
doubled from 85 
per 10,000 visits in 
2013 to 168 per 
10,000 visits in 
2014 (p=0.001).  No 
significant change 
in ED rates between 
2013 and 2014 
among CO residents 
were observed 
between 2013 and 
2014.    The rates 
did not change 
significantly 
between 2012 and 
2013 among out of 




related to cannabis 
use appear to be 
increasing more 
rapidly among out-
of-state residents 
compared to 
Colorado residents. 
 
